Galena

With Marina Biotech's back against the wall, the RNAi drugs field may soon see the departure of its third player this year, following the bankruptcy of Traversa Therapeutics and the acquisition of Tacere Therapeutics by Benitec Biopharma.

Galena Biopharma, the former parent firm of RXi Pharmaceuticals, has settled four lawsuits filed by investor groups that had raised questions about its now-completed spinout of the RNAi drug developer.

Galena Biopharma late last month completed its spinout of RNAi drugs subsidiary RXi Pharmaceuticals, ending a year-long saga that included an acquisition, litigation, and a management shakeup that included the loss of RXi's CSO.

Galena Biopharma this week said that it has taken steps to end a dispute with investors that threatened to block the company's planned spinout of RNAi subsidiary RXi Pharmaceuticals.

Using DNA to sketch crime victims might not be a great idea, the NYTimes says.

Science has its own problem with sexual harassment. What do we do with the research these abusers produce, Wired asks.

Senate Republicans led by Senator Rand Paul (R-KY) are trying to change how the government funds basic research, reports ScienceInsider.

In Science this week: combining genomics and ecology to better understand the effects of natural selection on evolution, and more.